Fallopian Tube Cancer
📧 Sign up to get email alerts when something new happens for Fallopian Tube Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer [Phase 1]
Phase 1 trial evaluating surgery and chemotherapy with or without additional chemotherapy after surgery for ovarian, fallopian tube, uterine…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: A Study of Lorigerlimab in Participants With Advanced Solid Tumors [Phase 2]
This is a Phase 2 clinical trial update for Lorigerlimab in participants with advanced solid tumors, currently recruiting, including platinu…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
This clinical trial update describes characterizing epithelial ovarian cancer patients by homologous recombination phenotype. The study is c…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer [Phase 2]
This is a Phase 2 neoadjuvant trial evaluating Aitua, a PD-1/CTLA-4 bispecific, with nab-paclitaxel and carboplatin in advanced high-grade s…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery [EARLY_Phase 1]
An early-phase clinical trial is evaluating olaparib for newly diagnosed BRCA-mutant ovarian, fallopian tube, or primary peritoneal cancers …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Artificial Intelligence - Assisted Model for Optimal Timing of Surgery in Advanced Ovarian Cancer
A clinical trial update from Shanghai Gynecologic Oncology Group describes an active-but-not-recruiting study evaluating an AI-assisted mode…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer [Phase 3]
A Phase 3 clinical trial is evaluating mirvetuximab soravtansine plus bevacizumab versus bevacizumab alone as maintenance therapy in platinu…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: First in Human Study of IMGN151 in Recurrent Gynaecological Cancers [Phase 1]
This update covers the first-in-human Phase 1 study of IMGN151 in recurrent gynecologic cancers, sponsored by AbbVie, with the trial status …
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]
This document provides a status update on a Phase 2 clinical trial evaluating adavosertib with or without olaparib for recurrent ovarian, fa…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Genomic BRCA and Extensive ovArian Cancer Testing
A completed clinical trial evaluated BRCA genomic testing and extensive ovarian cancer testing in epithelial ovarian cancer, primary periton…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube [EARLY_Phase 1]
An early-phase clinical trial is evaluating the effects of short-term aspirin on biological and immunologic changes in the Fallopian tube, i…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy [Phase 2]
This Phase II randomized, open-label trial evaluates whether NiraParib maintenance after 3 cycles of platinum-based chemotherapy is non-infe…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Italy
AbbVie-sponsored clinical study in Italy to evaluate folate receptor alpha expression in adults with ovarian, fallopian tube, or primary per…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
This Phase 2 trial is evaluating the combination of lenvatinib, pembrolizumab, and paclitaxel for recurrent endometrial, ovarian, fallopian …
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer [EARLY_Phase 1]
This is a Phase 1 trial evaluating hyperthermic intraperitoneal chemotherapy with cisplatin during or before surgery for Stage III/IV ovaria…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer [Phase 2]
Phase 2 clinical trial evaluating PLX038 for metastatic platinum-resistant ovarian cancer, fallopian tube cancer, and primary peritoneal can…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery [Phase 2]
Bevacizumab is being studied in a Phase 2 trial for ovarian cancer patients undergoing second-look surgery. The trial is currently active bu…
-
EMA approval · 2026-02-05EMA Authorised: Avzivi (bevacizumab) — FGK Representative Service GmbH
EMA authorised Avzivi (bevacizumab) for multiple indications including colorectal cancer, non-small cell lung cancer, renal cell carcinoma, …
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers [Phase 1]
Phase 1 trial to evaluate the safety and preliminary effectiveness of 27T51, a MUC16-targeting immune cell therapy, in adults with recurrent…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2
A prospective cohort trial is recruiting germline BRCA1/BRCA2 variant carriers to study cancer risk in ovarian, fallopian tube, and primary …
-
CLINICAL_TRIALS other · 2026-01-29Clinical Trial Update: Diet, Hepcidin, and Chemotherapy RDI
George Washington University announces an active-not-recruiting clinical trial evaluating how diet and hepcidin affect chemotherapy dose int…
-
EMA approval · 2026-01-28EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Abevmy (bevacizumab) as a biosimilar. It is approved for several cancer indications including colorectal, breast, ovarian, fa…
-
EMA approval · 2026-01-28EMA Authorised: Oyavas (bevacizumab) — STADA Arzneimittel AG
EMA authorised Oyavas, a bevacizumab biosimilar by STADA, for multiple indications including colorectal, breast, ovarian, fallopian tube, pe…
-
EMA approval · 2026-01-28EMA Authorised: Vegzelma (bevacizumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Vegzelma, a bevacizumab biosimilar from Celltrion Healthcare Hungary Kft., for multiple cancers including colorectal, breast,…
-
EMA approval · 2026-01-28EMA Authorised: Aybintio (bevacizumab) — Samsung Bioepis NL B.V.
The EMA authorised Aybintio, a bevacizumab biosimilar from Samsung Bioepis NL B.V., for multiple cancer indications including colorectal, br…